Double inhibition of NF-κB and XIAP via RNAi enhances the sensitivity of pancreatic cancer cells to gemcitabine

Cao,Li-Ping; Song,Jian-Lin; Yi,Xiao-Ping; Li,Yi-Xiong

doi:10.3892/or.2013.2246

Double inhibition of NF-κB and XIAP via RNAi enhances the sensitivity of pancreatic cancer cells to gemcitabine

Authors:
- Li-Ping Cao
- Jian-Lin Song
- Xiao-Ping Yi
- Yi-Xiong Li
View Affiliations

Affiliations: Department of General Surgery, Xiangya Hospital, Central South University, Hunan 410008, P.R. China, Department of Radiology, Xiangya Hospital, Central South University, Hunan 410008, P.R. China
Published online on: January 23, 2013 https://doi.org/10.3892/or.2013.2246
Pages: 1659-1665

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The majority of patients with pancreatic cancer are resistant to gemcitabine. One of the mechanisms involved is the anti-apoptotic ability of these cells. The median lethal dose (LD50) of gemcitabine for PANC-1 cells was higher than that for Mia PaCa-2 cells and the former had higher nuclear factor-κB (NF-κB) and X-linked inhibitor of apoptosis protein (XIAP) levels. NF-κB contributes to the inhibition of apoptosis by the downregulation of downstream genes, such as XIAP and Bcl-2 and it confers chemoresistance. The two cell lines were infected with NF-κB p65 small interfering RNA (siRNA). p65 protein was effectively downregulated accompanied by the downregulation of XIAP protein. The combination treatment with gemcitabine and p65 siRNA increased the apoptotic rates in both cell lines; however, this was not sufficient. XIAP is involved in apoptosis to a greater extent compated to Bcl-2. XIAP may serve as another factor affecting the sufficiency of chemotherapy. XIAP siRNA was designed to knockdown XIAP. Mia PaCa-2 and PANC-1 cells were co-infected with XIAP siRNA and p65 siRNA. XIAP and p65 proteins were effectively downregulated and the gemcitabine-induced apoptotic rates were significantly increased. These results suggest that XIAP and NF-κB are two important factors conferring the chemoresistance of pancreatic cancer cells, and that their downregulation via RNAi effectively enhances the chemosensitivity of pancreatic cancer cells to gemcitabine.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2	Tempero MA, Arnoletti JP, Behrman SW, et al: Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw. 10:703–713. 2012.PubMed/NCBI
3	Cunningham D, Chau I, Stocken DD, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 27:5513–5518. 2009. View Article : Google Scholar : PubMed/NCBI
4	Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
5	Raguz S and Yague E: Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer. 99:387–391. 2008. View Article : Google Scholar : PubMed/NCBI
6	Arlt A, Muerkoster SS and Schafer H: Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. November 13–2010. View Article : Google Scholar
7	Wan F and Lenardo MJ: The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives. Cell Res. 20:24–33. 2010. View Article : Google Scholar : PubMed/NCBI
8	Sebens S, Arlt A and Schafer H: NF-kappaB as a molecular target in the therapy of pancreatic carcinoma. Recent Results Cancer Res. 177:151–164. 2008. View Article : Google Scholar : PubMed/NCBI
9	Kanarek N, London N, Schueler-Furman O and Ben-Neriah Y: Ubiquitination and degradation of the inhibitors of NF-kappaB. Cold Spring Harb Perspect Biol. 2:a0001662010. View Article : Google Scholar : PubMed/NCBI
10	Biswas DK, Martin KJ, McAlister C, et al: Apoptosis caused by chemotherapeutic inhibition of nuclear factor-kappaB activation. Cancer Res. 63:290–295. 2003.PubMed/NCBI
11	Gyrd-Hansen M and Meier P: IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer. 10:561–574. 2010. View Article : Google Scholar : PubMed/NCBI
12	Eckelman BP, Salvesen GS and Scott FL: Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 7:988–994. 2006. View Article : Google Scholar : PubMed/NCBI
13	Chandler NM, Canete JJ and Callery MP: Increased expression of NF-kappa B subunits in human pancreatic cancer cells. J Surg Res. 118:9–14. 2004. View Article : Google Scholar : PubMed/NCBI
14	Weichert W, Boehm M, Gekeler V, et al: High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer. 97:523–530. 2007. View Article : Google Scholar : PubMed/NCBI
15	Arlt A, Gehrz A, Muerkoster S, et al: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 22:3243–3251. 2003. View Article : Google Scholar : PubMed/NCBI
16	Kong R, Sun B, Jiang H, et al: Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett. 291:90–98. 2010. View Article : Google Scholar : PubMed/NCBI
17	Pan X, Arumugam T, Yamamoto T, et al: Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res. 14:8143–8151. 2008. View Article : Google Scholar : PubMed/NCBI
18	Kashkar H: X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise. Clin Cancer Res. 16:4496–4502. 2010. View Article : Google Scholar : PubMed/NCBI
19	Shrikhande SV, Kleeff J, Kayed H, et al: Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells. Anticancer Res. 26:3265–3273. 2006.PubMed/NCBI
20	Lopes RB, Gangeswaran R, McNeish IA, Wang Y and Lemoine NR: Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer. 120:2344–2352. 2007. View Article : Google Scholar : PubMed/NCBI
21	Li Y, Jian Z, Xia K, et al: XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas. 32:288–296. 2006. View Article : Google Scholar : PubMed/NCBI
22	Fan Y, Dutta J, Gupta N, Fan G and Gelinas C: Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol. 615:223–250. 2008. View Article : Google Scholar : PubMed/NCBI
23	Liptay S, Weber CK, Ludwig L, Wagner M, Adler G and Schmid RM: Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer. 105:735–746. 2003. View Article : Google Scholar : PubMed/NCBI
24	Trauzold A, Schmiedel S, Roder C, et al: Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer. 89:1714–1721. 2003. View Article : Google Scholar : PubMed/NCBI
25	Oh JH, Cho MC, Kim JH, et al: IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals. Oncogene. 30:3345–3359. 2011.
26	Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S and Aggarwal BB: Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol. 69:195–206. 2006.PubMed/NCBI
27	Manna SK, Aggarwal RS, Sethi G, Aggarwal BB and Ramesh GT: Morin (3,5,7,2′,4′-Pentahydroxyflavone) abolishes nuclear factor-kappaB activation induced by various carcinogens and inflammatory stimuli, leading to suppression of nuclear factor-kappaB-regulated gene expression and up-regulation of apoptosis. Clin Cancer Res. 13:2290–2297. 2007.
28	Moon DO, Kim MO, Lee JD and Kim GY: Gossypol suppresses NF-kappaB activity and NF-kappaB-related gene expression in human leukemia U937 cells. Cancer Lett. 264:192–200. 2008. View Article : Google Scholar : PubMed/NCBI
29	Hannon GJ: RNA interference. Nature. 418:244–251. 2002. View Article : Google Scholar : PubMed/NCBI
30	Bilim V, Yuuki K, Itoi T, et al: Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. Br J Cancer. 98:941–949. 2008. View Article : Google Scholar : PubMed/NCBI
31	Kunze D, Wuttig D, Fuessel S, et al: Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells. Anticancer Res. 28:2259–2263. 2008.PubMed/NCBI
32	Ruckert F, Samm N, Lehner AK, Saeger HD, Grutzmann R and Pilarsky C: Simultaneous gene silencing of Bcl-2, XIAP and Survivin re-sensitizes pancreatic cancer cells towards apoptosis. BMC Cancer. 10:3792010. View Article : Google Scholar : PubMed/NCBI
33	Liston P, Fong WG and Korneluk RG: The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene. 22:8568–8580. 2003. View Article : Google Scholar : PubMed/NCBI
34	Seeger JM, Brinkmann K, Yazdanpanah B, et al: Elevated XIAP expression alone does not confer chemoresistance. Br J Cancer. 102:1717–1723. 2010. View Article : Google Scholar : PubMed/NCBI